Влияние комбинированного контрацептива с хлормадинона ацетатом на дерматологический и психосоциальный статус пациенток с акне

Воробьева Н.Е., Тарасова М.А. Влияние комбинированного контрацептива с хлормадинона ацетатом на дерматологический и психосоциальный статус пациенток с акне. Гинекология. 2016; 18 (1): 74–78.

________________________________________________

Vorobyova N.E., Tarasova M.A. The effect of the combined contraceptive with chlormadinone acetate in the dermatological and psychosocial status of patients with acne. Gynecology. 2016; 18 (1): 74–78

Читать PDF

Аннотация

Статья посвящена оценке эффективности лечения угревых высыпаний разной степени тяжести при использовании комбинированного гормонального контрацептива Белара® и его влиянию на показатели психологического и социального состояния у женщин репродуктивного возраста. Обследованы 123 пациентки, заинтересованные в контрацепции, в возрасте 18–45 лет с угревыми высыпаниями на лице различной степени тяжести. Проведено анкетирование по субъективной и объективной оценке состояния кожи и наличию психологических и социальных проблем, связанных с угревой болезнью, до назначения, через 3 и 6 циклов приема препарата Белара®. Показано, что комбинированный оральный контрацептив Белара®, содержащий в своем составе этинилэстрадиол и хлормадинона ацетат, обладает хорошей переносимостью и эффективно улучшает состояние кожи у пациенток с акне, что положительно отражается на их психологической, эмоциональной и социальной самооценке. Высокую удовлетворенность препаратом отметили 87% пациенток.

Ключевые слова: акне, состояние кожи, хлормадинона ацетат, Белара, дерматологический и социальный статус.

________________________________________________

The article is about assessing the effectiveness of the treatment of acne of varying severity using a combined hormonal contraceptive Belara® and its impact on the indicators of psychological and social status of women of reproductive age. The study included 123 women interested in contraception, aged 18–45 years old with acne on the face of varying severity. A survey on subjective and objective assessment of the condition of the skin and the presence of psychological and social problems associated with acne, after 3 and 6 cycles of using Belara®. It has been shown that the combined oral contraceptive Belara® containing in its composition ethinylestradiol and chlormadinone acetate, is well tolerated and effective in improving skin condition in patients with acne, that has a positive impact on their psychological, emotional and social self-esteem. High satisfaction drug indicated 87% of the patients.

Key words: acne, skin condition, chlormadinone acetate, Belara, dermatological and social status.

Полный текст

Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Goulden V, Stables G, Gunliffe W. Prevalence of facial acne in adults. J Fv Acad Derm 1999; 44: 577–80.
2. Zouboulis CC. The human skin as a hormone target and an endocrine gland. Hormones 2004; 3 (1): 9–26.
3. Held BL, Nader S, Rodriguez-Rigau LJ et al. Acne and hyperandrogenism. J Am Acad Dermatol 1984; 10 (2 Pt. 1): 223–6.
4. Lucky AW. Hormonal correlates of acne and hirsutism. Am J Med 1995; 98 (1A): 89S–94S.
5. Rosenfield RL, Deplewski D. Role of androgens in the developmental biology of the pilosebaceous unit. Am J Med 1995; 98 (1A): 80S–88S.
6. Huber JC, Heskamp ML, Schramm GA. Effect of an oral contraceptive with chlormadinone acetate on depressive mood: analysis of data from four observational studies. Clin Drug Investig 2008; 28 (12): 783–91.
7. Vasques MG, Amayueles RN, Lamarca M et al. Ethinylestradiol/Chlormadinon acetate for use in dermatological disorders. Am J Clin Dermatol 2011; 12 (Suppl. 1): 13–9.
8. Guerra-Tapia A, Sancho Pérez B. Ethinylestradiol/Chlormadinone acetate: dermatological benefits. Am J Clin Dermatol 2011; 12 (Suppl. 1): 3–11.
9. Шестакова И.Г., Бриль Ю.А. Женские андрогены: ищем золотую середину. StatusPrezens. 2014; 4 (21): 55–60. / Shestakova I.G., Bril' Iu.A. Zhenskie androgeny: ishchem zolotuiu seredinu. StatusPrezens. 2014; 4 (21): 55–60. [in Russian]
10. Kerscher M, Reuther T, Bayrhammer J, Schramm G. Effects of an oral contraceptive containing chlormadinone and ethinylestradiol on acne-prone skin of women of different age groups: an open-label, single-centre, phase IV study. Clin Drug Investig 2008; 28 (11): 703–11.
11. Térouanne B, Paris F, Servant N et al. Evidence that chlormadinone acetate exhibits antiandrogenic activity in androgen-dependent cell line. Mol Cell Endocrinol 2002; 198 (1–2): 143–7.
12. Schramm G, Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0,03 mg (BelaraR). Results of a post-marketing surveillance study. Clin Drug Invest 2002; 22: 221–31.
13. Schramm G, Steffens D. F 12-month evaluation of the CMA-containing pral contraceptive Belara: efficacy, tolerability and anti-androgenic properties. Contraception 2003; 67: 305–12.
14. Zahradnik H, Goldberg J, Andreas J. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception 1998; 57: 103–9.
15. Zahradnik HP, Hanjalic-Dtck A. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles) – an open-label, prospective, noncontrolled, office-based Phase III study. Contraception 2008; 77: 337–43.
16. Arowojolu AO, Gallo MF, Lopez LM et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2007; CD004425.
17. Worret I, Arp W, Zahradnik HP et al. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 2001; 203 (1): 38–44.

________________________________________________

1. Goulden V, Stables G, Gunliffe W. Prevalence of facial acne in adults. J Fv Acad Derm 1999; 44: 577–80.
2. Zouboulis CC. The human skin as a hormone target and an endocrine gland. Hormones 2004; 3 (1): 9–26.
3. Held BL, Nader S, Rodriguez-Rigau LJ et al. Acne and hyperandrogenism. J Am Acad Dermatol 1984; 10 (2 Pt. 1): 223–6.
4. Lucky AW. Hormonal correlates of acne and hirsutism. Am J Med 1995; 98 (1A): 89S–94S.
5. Rosenfield RL, Deplewski D. Role of androgens in the developmental biology of the pilosebaceous unit. Am J Med 1995; 98 (1A): 80S–88S.
6. Huber JC, Heskamp ML, Schramm GA. Effect of an oral contraceptive with chlormadinone acetate on depressive mood: analysis of data from four observational studies. Clin Drug Investig 2008; 28 (12): 783–91.
7. Vasques MG, Amayueles RN, Lamarca M et al. Ethinylestradiol/Chlormadinon acetate for use in dermatological disorders. Am J Clin Dermatol 2011; 12 (Suppl. 1): 13–9.
8. Guerra-Tapia A, Sancho Pérez B. Ethinylestradiol/Chlormadinone acetate: dermatological benefits. Am J Clin Dermatol 2011; 12 (Suppl. 1): 3–11.
9. Shestakova I.G., Bril' Iu.A. Zhenskie androgeny: ishchem zolotuiu seredinu. StatusPrezens. 2014; 4 (21): 55–60. [in Russian]
10. Kerscher M, Reuther T, Bayrhammer J, Schramm G. Effects of an oral contraceptive containing chlormadinone and ethinylestradiol on acne-prone skin of women of different age groups: an open-label, single-centre, phase IV study. Clin Drug Investig 2008; 28 (11): 703–11.
11. Térouanne B, Paris F, Servant N et al. Evidence that chlormadinone acetate exhibits antiandrogenic activity in androgen-dependent cell line. Mol Cell Endocrinol 2002; 198 (1–2): 143–7.
12. Schramm G, Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0,03 mg (BelaraR). Results of a post-marketing surveillance study. Clin Drug Invest 2002; 22: 221–31.
13. Schramm G, Steffens D. F 12-month evaluation of the CMA-containing pral contraceptive Belara: efficacy, tolerability and anti-androgenic properties. Contraception 2003; 67: 305–12.
14. Zahradnik H, Goldberg J, Andreas J. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception 1998; 57: 103–9.
15. Zahradnik HP, Hanjalic-Dtck A. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles) – an open-label, prospective, noncontrolled, office-based Phase III study. Contraception 2008; 77: 337–43.
16. Arowojolu AO, Gallo MF, Lopez LM et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2007; CD004425.
17. Worret I, Arp W, Zahradnik HP et al. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 2001; 203 (1): 38–44.

Авторы

Н.Е.Воробьева*, М.А.Тарасова

ФГБНУ НИИ акушерства, гинекологии и репродуктологии им. Д.О.Отта. 199034, Россия, Санкт-Петербург, Менделеевская линия, д. 3
*sergiognezdo@yandex.ru

________________________________________________

N.E.Vorobyova*, M.A.Tarasova

D.O.Ott Research Institute of Obstetrics, Gynecology and Reproduction. 199034, Russian Federation, Saint Petersburg, Mendeleevskaia liniia, d. 3
*sergiognezdo@yandex.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.